Cryptocurrencies: 3,850
Markets: 22,658
ICO's: 4,983
Market Cap: $275,286,078,961
24h Vol: $80,657,630,249
Dominance: 64.7%
 Xeophin (PreICO)

Xeophin (PreICO)

Developing a suite of Class Leading Immunotherapeutics

Website

Xeophin has devised a funding pathway to develop the XeRA-1 Therapeutic for Rheumatoid Arthritis, however this offering represents much more than stake in a promising pharmaceutical. Xeophins’ unique approach to Biotech funding can change the paradigm of how medicine is financed. Xeophin is tokenizing 50% of the future royalties generated by XeRA-1, allowing its’ token holders to fund, and benefit from its’ success. Our mission is to take our core technologies and drive them through our six step process. The outcome being a transaction-ready and IP protected technology portfolio, tokenized. From then on, Xeophin will undertake commercialization activities to achieve a significant royalty deal, delivering value to our XeRA-1 Token holders. Being backed by a physical asset, the XeRA-1 Arthritis Therapeutic, the XERA1 token can increase in value as milestones are hit on the road to commercialization. Once live, token holders will yield cash royalty payments, commensurate to XeRA-1s’ earnings.


About Xeophin (PreICO)

Xeophin Pt y Ltd is a Melbourne, Australia based, Biotech Company with a focus on imunomodulating technologies, and is commit ted to the research, development and commercialisation of new and novel medical treatment s, in a number of high grow th therapeutic areas such as inflammation.

Our mission and vision are simple: “Take our core technologies and drive them through our six step process. The outcome being a transaction ready and IP protected technolog y por t folio. From this Xeophin will under take commercialisation activities to achieve a significant royalt y deal, delivering value to our XeR A-1 Token holders”.

In his position as Chief Executive Of ficer, Troy Neilson brings significant, relevant and recent Biotech experience along with extensive management skills. Travis Molloy as Executive Chairman brings 15 years experience in the development stage Biotech space and governance. Caroline Cook as Non-Executive Director brings to the organisation a wealth of project management, outsourcing and leadership experience.

Xeophin is currently a private and unlisted Australian company. Formal policies and best practice from Corporate Governance to Financial Management have been implemented from inception. Xeophin will reorganise and transition it self into the USA , this entit y is referred to NewCo at this stage. It is the NewCo entit y that will seek SEC compliance and undertake the formal ICO*.

The Team

Travis Molloy Bsc

EXECUTIVE CHAIRMAN

Troy Neilson

CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR

Jason Yeates

CHIEF FINANCIAL OFFICER, SENIOR VICE PRESIDENT OF BUSINESS DEVELOPMENT & COLLABORATIONS

Goran Ando

CHAIRMAN, CLINICAL ADVISORY COMMITTEE

Patrick Mcmanamny

HEAD OF INTELLECTUAL PROPERTY

Susan Dexter

HEAD OF CMC & GMP

Caroline Cook

NON-EXECUTIVE DIRECTOR

Financials

Token Info

Type
ERC20
Price in ICO
1 XERA = 1 USD
Tokens for sale
345,450,000

Investment Info

Min. investment
1 USD
Distributed in ICO
49,35%

Related ICOs

Name Status Start Date End Date Total Supply Category Listing
Geco.one
Active
Dec 24th Dec 25th 550,000,000 Platform
Basic